Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Gene expression signatures of primary and metastatic uterine leiomyosarcoma.

Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL.

Hum Pathol. 2014 Apr;45(4):691-700. doi: 10.1016/j.humpath.2013.11.003. Epub 2013 Nov 13.

2.

Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.

Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL.

Gynecol Oncol. 2013 Feb;128(2):349-55. doi: 10.1016/j.ygyno.2012.11.021. Epub 2012 Nov 21.

3.

Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.

Ravid Y, Formanski M, Smith Y, Reich R, Davidson B.

Gynecol Oncol. 2016 Mar;140(3):512-7. doi: 10.1016/j.ygyno.2016.01.001. Epub 2016 Jan 6.

PMID:
26768834
4.

Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.

Mills AM, Beck AH, Montgomery KD, Zhu SX, Espinosa I, Lee CH, Subramanian S, Fletcher CD, van de Rijn M, West RB.

Am J Surg Pathol. 2011 Apr;35(4):583-9. doi: 10.1097/PAS.0b013e318211abd6.

5.

Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.

Zhang P, Zhang C, Hao J, Sung CJ, Quddus MR, Steinhoff MM, Lawrence WD.

Hum Pathol. 2006 Oct;37(10):1350-6. Epub 2006 Jul 26.

PMID:
16949924
6.

Primary and secondary leiomyosarcoma of the oral and perioral region--clinicopathological and immunohistochemical analysis of a rare entity with a review of the literature.

Schütz A, Smeets R, Driemel O, Hakim SG, Kosmehl H, Hanken H, Kolk A.

J Oral Maxillofac Surg. 2013 Jun;71(6):1132-42. doi: 10.1016/j.joms.2012.12.011. Epub 2013 Feb 20. Review.

PMID:
23434173
7.
8.

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.

Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, Fletcher JA, Beck AH, West RB, Nusse R, van de Rijn M.

J Pathol. 2012 Jun;227(2):223-33. doi: 10.1002/path.3986. Epub 2012 Feb 17.

9.

Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.

Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IeM, Wang TL.

J Cell Mol Med. 2011 Mar;15(3):535-44. doi: 10.1111/j.1582-4934.2010.01023.x.

10.

Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.

Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, Morton CC.

Genes Chromosomes Cancer. 2004 Jun;40(2):97-108.

PMID:
15101043
11.

Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features.

Christacos NC, Quade BJ, Dal Cin P, Morton CC.

Genes Chromosomes Cancer. 2006 Mar;45(3):304-12.

PMID:
16320247
12.

Uterine leiomyosarcoma with osteoclast-like giant cells associated with high expression of receptor activator of nuclear factor κB ligand.

Terasaki M, Terasaki Y, Yoneyama K, Kuwahara N, Wakamatsu K, Nagahama K, Kunugi S, Takeshita T, Shimizu A.

Hum Pathol. 2015 Nov;46(11):1679-84. doi: 10.1016/j.humpath.2015.04.018. Epub 2015 Jul 21.

PMID:
26315618
14.

The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line.

Chuang TD, Ho M, Khorram O.

Reprod Sci. 2015 May;22(5):563-71. doi: 10.1177/1933719114553450. Epub 2014 Oct 9.

PMID:
25305131
15.

Metastatic leiomyosarcoma in the oral cavity: case report with protein expression profiles.

Kim SM, Myoung H, Choung PH, Kim MJ, Lee SK, Lee JH.

J Craniomaxillofac Surg. 2009 Dec;37(8):454-60. doi: 10.1016/j.jcms.2009.06.010. Epub 2009 Aug 6. Review.

PMID:
19664933
16.

Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.

Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S.

Cancer. 2004 Sep 15;101(6):1455-62.

17.

Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Int J Oncol. 2010 Sep;37(3):605-14.

PMID:
20664929
18.

Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.

Zhang Q, Ubago J, Li L, Guo H, Liu Y, Qiang W, Kim JJ, Kong B, Wei JJ.

Cancer. 2014 Oct 15;120(20):3165-77. doi: 10.1002/cncr.28900. Epub 2014 Jul 1.

19.

MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters.

Bodner-Adler B, Bodner K, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K.

J Soc Gynecol Investig. 2003 Oct;10(7):443-6.

PMID:
14519487
20.

Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.

Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kanai Y, Shiozawa T, Tonegawa S, Konishi I.

Protein Cell. 2010 Aug;1(8):711-7. doi: 10.1007/s13238-010-0095-x. Epub 2010 Aug 28. Review.

Supplemental Content

Support Center